A myeloperoxidase promoter polymorphism is independently associated with mortality in patients with impaired left ventricular function.

• Authors: RUDOLPH V; RUDOLPH TK; KUBALA Lukáš; CLAUBERG N; MAAS R; PEKAROVÁ Michaela; KLINKE A; LAU D; SZÖCS Katalin; MEINERTZ T; BÖGER RH; BALDUS S
• Year of publication: 2009
• Type: Article in Periodical
• Magazine / Source: FREE RADICAL BIOLOGY AND MEDICINE
• MU Faculty or unit: Faculty of Science
• Web: http://www.ncbi.nlm.nih.gov/pubmed/19735726
• Doi: http://dx.doi.org/10.1016/j.freeradbiomed.2009.09.001
• Keywords: Myeloperoxidase; Genetics; Heart failure; Survival; Free radicals
• Description: Circulating levels of myeloperoxidase (MPO), a heme enzyme released upon activation of polymorphonuclear neutrophils, predict adverse outcome in patients with impaired left ventricular (LV) function.Interestingly, we observed no association of the MPO polymorphism with total MPO protein concentration or MPO activity in plasma. The 463 GA MPO polymorphism is linked to adverse clinical outcome of patients with impaired LV function. Further studies are needed to elucidate the value of this polymorphism for risk stratification.